Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912190 | 0.88 | CYP26A1 (0.55) | SMN1; SMN2NPC1POLBKDM4EHTT | |
| SCHEMBL13655065 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1ALDH1A1CYP19A1POLB | |
| SCHEMBL436331 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1POLBKDM4EHTT | |
| SCHEMBL1109352 | 0.73 | HDAC4 (0.47) | MAPK1 | |
| SCHEMBL1109333 | 0.71 | KDM4E (0.54) | SMN1; SMN2NPC1ALDH1A1POLBKDM4E | |
| SCHEMBL1109426 | 0.71 | GRIN1 (0.52) | — | |
| SCHEMBL10287211 | 0.69 | SLC6A2 (0.38) | CYP26A1 | |
| SCHEMBL14082170 | 0.69 | NAMPT (0.67) | SMN1; SMN2NPC1ALDH1A1CYP19A1POLB | |
| SCHEMBL1109442 | 0.68 | L3MBTL1 (0.49) | SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL14082497 | 0.68 | NPC1 (0.68) | SMN1; SMN2NPC1ALDH1A1CYP19A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | SMN1; SMN2 2296/4885NPC1 371/4885ALDH1A1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.